MEDIA CENTER2018-11-19T17:53:23-06:00

Latest news from Rapha Capital Management & our portfolio companies

NexImmune Inc.
NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome

  • ND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplant
  • IND clearance validates Company’s Artificial Immune Modulation (AIM) nanoparticle technology platform
  • Subsequent IND submission to evaluate NEXI-002 in relapsed / refractory Multiple Myeloma patients expected before end of 2019

October 30, 2019

Go to Top